115 related articles for article (PubMed ID: 2028443)
41. [Heparin cofactor II and thrombophilic conditions].
Hudecek J; Hal'áková E; Ivanková J; Kubisz P
Vnitr Lek; 1997 May; 43(5):317-9. PubMed ID: 9601856
[TBL] [Abstract][Full Text] [Related]
42. Antithrombin III and heparin cofactor II in patients with chronic renal failure undergoing regular hemodialysis.
Toulon P; Jacquot C; Capron L; Frydman MO; Vignon D; Aiach M
Thromb Haemost; 1987 Jun; 57(3):263-8. PubMed ID: 3660328
[TBL] [Abstract][Full Text] [Related]
43. [Effect of heparin cofactor II on the antithrombin III activities measured by thrombin methods or factor Xa methods--fundamental studies and clinical studies using the plasma of pregnant women].
Akai Y; Shiga S; Tohyama K; Shimatsu A; Ichiyama S
Rinsho Byori; 2000 Sep; 48(9):867-71. PubMed ID: 11051806
[TBL] [Abstract][Full Text] [Related]
44. Heparin cofactor II levels are increased by the use of combined oral contraceptives.
Mackie IJ; Segal H; Burren T; Gallimore M; Walshe KJ; Robinson G; Machin SJ
Blood Coagul Fibrinolysis; 1990 Dec; 1(6):647-51. PubMed ID: 2133244
[TBL] [Abstract][Full Text] [Related]
45. Heparin cofactor II activity in plasma: application of an automated assay method to the study of a normal adult population.
Andersson TR; Larsen ML; Handeland GF; Abildgaard U
Scand J Haematol; 1986 Jan; 36(1):96-102. PubMed ID: 3754062
[TBL] [Abstract][Full Text] [Related]
46. Thrombin-based antithrombin assays show overestimation of antithrombin III activity in patients on heparin therapy due to heparin cofactor II influence.
Bohner J; von Pape KW; Blaurock M
Thromb Haemost; 1994 Mar; 71(3):280-3. PubMed ID: 8029789
[TBL] [Abstract][Full Text] [Related]
47. [Constitutional dysfunction of heparin cofactor II with a tendency for venous thrombosis].
Marbet GA; Zbinden B; Duckert F
Schweiz Med Wochenschr; 1988 Oct; 118(43):1586-8. PubMed ID: 3238395
[TBL] [Abstract][Full Text] [Related]
48. Antithrombin III- and heparin cofactor II-mediated anticoagulant and antiprotease actions of heparin and its synthetic analogues.
Jeske W; Fareed J
Semin Thromb Hemost; 1993; 19 Suppl 1():241-7. PubMed ID: 8362268
[TBL] [Abstract][Full Text] [Related]
49. Dermatan sulfate and heparin can be fractionated by affinity for heparin cofactor II.
Griffith MJ; Marbet GA
Biochem Biophys Res Commun; 1983 Apr; 112(2):663-70. PubMed ID: 6687802
[TBL] [Abstract][Full Text] [Related]
50. The role of heparin cofactor II in the modulation of hemostasis.
Salem HH; Thompson EA
Dev Biol Stand; 1987; 67():67-72. PubMed ID: 3301469
[TBL] [Abstract][Full Text] [Related]
51. Modulation of heparin cofactor II activity by histidine-rich glycoprotein and platelet factor 4.
Tollefsen DM; Pestka CA
J Clin Invest; 1985 Feb; 75(2):496-501. PubMed ID: 3838317
[TBL] [Abstract][Full Text] [Related]
52. Mechanisms for inhibition of the generation of thrombin activity by sulfated polysaccharides.
Ofosu FA; Modi GJ; Hirsh J; Buchanan MR; Blajchman MA
Ann N Y Acad Sci; 1986; 485():41-55. PubMed ID: 2436525
[TBL] [Abstract][Full Text] [Related]
53. Prevention of thrombus formation and growth by antithrombin III and heparin cofactor II-dependent thrombin inhibitors: importance of heparin cofactor II.
Buchanan MR; Liao P; Smith LJ; Ofosu FA
Thromb Res; 1994 Jun; 74(5):463-75. PubMed ID: 8085247
[TBL] [Abstract][Full Text] [Related]
54. Prothrombin G20210A gene mutation, heparin cofactor II defects, primary (essential) thrombocythemia, and thrombohemorrhagic manifestations.
Frenkel EP; Bick RL
Semin Thromb Hemost; 1999; 25(4):375-86. PubMed ID: 10548071
[TBL] [Abstract][Full Text] [Related]
55. In vivo catabolism of heparin cofactor II and its complex with thrombin: evidence for a common receptor-mediated clearance pathway for three serine proteinase inhibitors.
Pratt CW; Church FC; Pizzo SV
Arch Biochem Biophys; 1988 Apr; 262(1):111-7. PubMed ID: 3258496
[TBL] [Abstract][Full Text] [Related]
56. [Recurrent venous thromboembolism caused by heparin cofactor II deficiency. A case].
Schved JF; Gris JC; Aguilar-Martinez P; Birbes P; Carabalona P
Presse Med; 1991 Jul 6-13; 20(26):1211-4. PubMed ID: 1831893
[TBL] [Abstract][Full Text] [Related]
57. Effect of low molecular weight heparin preparations on the inhibition of thrombin by heparin cofactor II.
Tollefsen DM; Sugimori T; Maimone MM
Semin Thromb Hemost; 1990 Oct; 16 Suppl():66-70. PubMed ID: 1962908
[TBL] [Abstract][Full Text] [Related]
58. Influence of the oversulfation method and the degree of sulfation on the anticoagulant properties of dermatan sulfate derivatives.
Maaroufi RM; Tapon-Bretaudiere J; Mardiguian J; Sternberg C; Dautzenberg MD; Fischer AM
Thromb Res; 1990 Aug; 59(4):749-58. PubMed ID: 2080493
[TBL] [Abstract][Full Text] [Related]
59. Anti-thrombin activities of heparin. Effect of saccharide chain length on thrombin inhibition by heparin cofactor II and by antithrombin.
Bray B; Lane DA; Freyssinet JM; Pejler G; Lindahl U
Biochem J; 1989 Aug; 262(1):225-32. PubMed ID: 2818566
[TBL] [Abstract][Full Text] [Related]
60. Inhibition of factor X, factor V and prothrombin activation by the bis(lactobionic acid amide) LW10082.
Ofosu FA; Fareed J; Smith LM; Anvari N; Hoppensteadt D; Blajchman MA
Eur J Biochem; 1992 Jan; 203(1-2):121-5. PubMed ID: 1730217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
